Autologous transplantation performed in relapsed disease or partial remission (based on Reference1 ).
| Author (No. Pts.) . | Conditioning . | In Vitro Purging . | Stem Cell Source . | Median Follow Up (mo.) . | PFS . | OS . | Early TRM* . | Comments . |
|---|---|---|---|---|---|---|---|---|
| *Early treatment-related mortality (TRM), usually defined as occurring within 100 days after ASCT. | ||||||||
| Abbreviations: PFS, progression-free survival; OS, overall survival; MoAB, monoclonal antibody; VP, etoposide; BM, bone marrow; PB, peripheral blood; NS, not stated; BEAM, BCNU/etoposide/cytarabine/melphalan; BEAC, BCNU/etoposide/cytarabine/cyclophosphamide; Bu/Cy, busulfan/cyclophosphamide; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; XPB; C′, complement; ASCT, autologous stem cell transplantation. | ||||||||
| Colombat (42) | Cy/TBI or BEAM | purging in 40% BM pts | BM 88%, PB 12% | 43 | 58% @ 43 mo | 83% @ 43 mo | ||
| Freedman (153) | Cy/TBI | Anti B MoAB + C′ | BM | 96 | 42% @ 8 yr | 66% @ 8 yr | <1% | 18 secondary malignancies (12 MDS) |
| Bierman (100) | Cy/TBI or BEAM | none | BM 13%, PB 87% | 31 | 44% @ 48 mo | 65% @ 48 mo | 8% | 2 secondary MDS |
| Apostolidis (99) | Cy/TBI | Anti B MoAB + C′ | BM | 66 | 63% @ 66 mo | 69% @ 66 mo | 4% | 12 secondary hematologic malignancies |
| Voso (41) | Cy/TBI 80% BEAM 20% | CD34+ selection in some pts | PB | 44 | 43% @ 44 mo | 72% @ 44 mo | 4% | 5% secondary malignancies |
| Bastion (48) | Cy/TBI | none | PB | 21 | 53% @ 21 mo | 86% @ 21 mo | 1 secondary MDS | |
| Weaver (49) | Bu/Cy or | none BEAC | PB | 42 | 35% @ 42 mo | 55% @ 42 mo | 8% | BuCy equivalent to BEAC |
| Berglund (22) | BEAC +/−TBI | MoAB in 9 pts. | BM | 74 | 72% @ 74 mo | 81% @ 74 mo | 50% transformed NHL | |
| Brice (83) | TBI 71%, BEAM 29% | CD34 22% | PB 73%, BM 27% | 44 | 42% @ 60 mo | 58% @ 60 mo | 29% transformed NHL | |
| Verdonck (18) | Cy/TBI | none | BM | 36 | 22% @ 24 mo | 33% @ 36 mo | ||
| Cervantes (34) | Cy/TBI 91%, | Anti B MoAB + C’ BEAM 9% | BM 70%, PB 27%, both 3% | 40 | 18% @ 24 mo | 37% @ 60 mo | 4% | |
| Cao (49) | Cy/TBI/VP 78% Cy/BCNU/VP 22% | Anti B MoAB | BM 39% PB 61% | 66 | 44% @ 48 mo | 60% @ 48 mo | ||
| Van Besien (597) | TBI 31% Non-TBI 69% | None | BM 15% PB 85% | 41 | 31% | 55% | 4% | TRM increases to 8% @ 5 yr |
| Van Besien (131) | TBI 34% Non-TBI 66% | MoAB 11% CD34+ selection 21% in vitro chemotherapy 68% | BM 76% PB 24% | 49 | 39% | 62% | 8% | TRM increases to 14% @ 5 yr |
| Schouten (65) | Cy/TBI | Anti B MoAB 50% | BM | 69 | 52% | 72% | Randomized study | |
| Molina (58) | Cy/VP and either BCNU or TBI | none | PB | 62 | 42% @ 60 mo | 67% @ 60 mo | 2% | 2 secondary MDS |
| Seyfarth (22) | Cy/TBI 38% BEAM or Bu/Cy 62% | CD34+ selection in 95% | PB | 48 | 38% @ 48 mo | 73% @ 48 mo | ||
| Stein (36) | Cy/VP/TBI 75% CBV 25% | none | BM 93% PB 7% | NS | NS | 53% | 15% | 1 secondary MDS |
| Author (No. Pts.) . | Conditioning . | In Vitro Purging . | Stem Cell Source . | Median Follow Up (mo.) . | PFS . | OS . | Early TRM* . | Comments . |
|---|---|---|---|---|---|---|---|---|
| *Early treatment-related mortality (TRM), usually defined as occurring within 100 days after ASCT. | ||||||||
| Abbreviations: PFS, progression-free survival; OS, overall survival; MoAB, monoclonal antibody; VP, etoposide; BM, bone marrow; PB, peripheral blood; NS, not stated; BEAM, BCNU/etoposide/cytarabine/melphalan; BEAC, BCNU/etoposide/cytarabine/cyclophosphamide; Bu/Cy, busulfan/cyclophosphamide; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; XPB; C′, complement; ASCT, autologous stem cell transplantation. | ||||||||
| Colombat (42) | Cy/TBI or BEAM | purging in 40% BM pts | BM 88%, PB 12% | 43 | 58% @ 43 mo | 83% @ 43 mo | ||
| Freedman (153) | Cy/TBI | Anti B MoAB + C′ | BM | 96 | 42% @ 8 yr | 66% @ 8 yr | <1% | 18 secondary malignancies (12 MDS) |
| Bierman (100) | Cy/TBI or BEAM | none | BM 13%, PB 87% | 31 | 44% @ 48 mo | 65% @ 48 mo | 8% | 2 secondary MDS |
| Apostolidis (99) | Cy/TBI | Anti B MoAB + C′ | BM | 66 | 63% @ 66 mo | 69% @ 66 mo | 4% | 12 secondary hematologic malignancies |
| Voso (41) | Cy/TBI 80% BEAM 20% | CD34+ selection in some pts | PB | 44 | 43% @ 44 mo | 72% @ 44 mo | 4% | 5% secondary malignancies |
| Bastion (48) | Cy/TBI | none | PB | 21 | 53% @ 21 mo | 86% @ 21 mo | 1 secondary MDS | |
| Weaver (49) | Bu/Cy or | none BEAC | PB | 42 | 35% @ 42 mo | 55% @ 42 mo | 8% | BuCy equivalent to BEAC |
| Berglund (22) | BEAC +/−TBI | MoAB in 9 pts. | BM | 74 | 72% @ 74 mo | 81% @ 74 mo | 50% transformed NHL | |
| Brice (83) | TBI 71%, BEAM 29% | CD34 22% | PB 73%, BM 27% | 44 | 42% @ 60 mo | 58% @ 60 mo | 29% transformed NHL | |
| Verdonck (18) | Cy/TBI | none | BM | 36 | 22% @ 24 mo | 33% @ 36 mo | ||
| Cervantes (34) | Cy/TBI 91%, | Anti B MoAB + C’ BEAM 9% | BM 70%, PB 27%, both 3% | 40 | 18% @ 24 mo | 37% @ 60 mo | 4% | |
| Cao (49) | Cy/TBI/VP 78% Cy/BCNU/VP 22% | Anti B MoAB | BM 39% PB 61% | 66 | 44% @ 48 mo | 60% @ 48 mo | ||
| Van Besien (597) | TBI 31% Non-TBI 69% | None | BM 15% PB 85% | 41 | 31% | 55% | 4% | TRM increases to 8% @ 5 yr |
| Van Besien (131) | TBI 34% Non-TBI 66% | MoAB 11% CD34+ selection 21% in vitro chemotherapy 68% | BM 76% PB 24% | 49 | 39% | 62% | 8% | TRM increases to 14% @ 5 yr |
| Schouten (65) | Cy/TBI | Anti B MoAB 50% | BM | 69 | 52% | 72% | Randomized study | |
| Molina (58) | Cy/VP and either BCNU or TBI | none | PB | 62 | 42% @ 60 mo | 67% @ 60 mo | 2% | 2 secondary MDS |
| Seyfarth (22) | Cy/TBI 38% BEAM or Bu/Cy 62% | CD34+ selection in 95% | PB | 48 | 38% @ 48 mo | 73% @ 48 mo | ||
| Stein (36) | Cy/VP/TBI 75% CBV 25% | none | BM 93% PB 7% | NS | NS | 53% | 15% | 1 secondary MDS |